Skip to Content

Early responses for BCMA-directed CAR-T cell therapy in progressive MM after 1-3 prior lines of therapy

Mounzer Agha, director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center, present data from CARTITUDE-2 study for patients with Multiple Myeloma, who had received 1–3 prior lines of therapy. In the CARTITUDE-2 study, the patients were treated with Ciltacabtagene autoleucel – a chimeric antigen receptor T (CAR-T) cell therapy expressing two B-cell maturation antigen (BCMA)-targeting, single-domain antibodies designed to confer avidity.

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Back to top